# Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

> **NCT01066468** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Chronic Myeloid Leukemia (CML)
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

## Interventions

- **DRUG:** Gleevec/Glivec

## Key facts

- **NCT ID:** NCT01066468
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066468, "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01066468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*